Polyunsaturated ω3 fatty acids prevent the cardiac hypertrophy in hypertensive rats

• Published in: Biochimica et biophysica acta. General subjects Vol. 1867; no. 2; p. 130278
• Main Authors: Zavala, M.R., Longarzo, M.L., Vázquez, R.F., Vélez Rueda, O., Maté, S.M., Villa-Abrille, M.C.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2023
• Subjects: Animals; body weight; Cardiac hypertrophy; cardiac output; Cardiomegaly - drug therapy; Cardiomegaly - prevention & control; cardiomyocytes; DHA; diet; docosahexaenoic acid; Docosahexaenoic Acids; echocardiography; Eicosapentaenoic Acid; EPA; Fatty Acids, Omega-3 - pharmacology; geometry; hypertrophy; lipid composition; membrane proteins; NHE1; Omega 3 polyunsaturated fatty acids; Rats; Rats, Inbred SHR; Rats, Wistar; SHR; systolic blood pressure; Cardiac hypertrophy; Omega 3 polyunsaturated fatty acids; NHE1; SHR; DHA; EPA
• DOI: 10.1016/j.bbagen.2022.130278
• ISSN: 0304-4165; 1872-8006

It has been demonstrated that supplementation with the two main omega 3 polyunsaturated fatty acids (ω3 FAs), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), leads to modifications in the cardiac physiology. ω3 FAs can affect the membrane's lipid composition, as well as proteins' location and/or function. The Na+/H+ exchanger (NHE1) is an integral membrane protein involved in the maintenance of intracellular pH and its hyperactivity has been associated with the development of various cardiovascular diseases such as cardiac hypertrophy. Our aim was to determine the effect of ω3 FAs on systolic blood pressure (SBP), lipid profiles, NHE1 activity, and cardiac function in spontaneously hypertensive rats (SHR) using Wistar rats (W) as normotensive control. After weaning, the rats received orally ω3 FAs (200 mg/kg body mass/day/ 4 months). We measured SBP, lipid profiles, and different echocardiography parameters, which were used to calculate cardiac hypertrophy index, systolic function, and ventricular geometry. The rats were sacrificed, and ventricular cardiomyocytes were obtained to measure NHE1 activity. While the treatment with ω3 FAs did not affect the SBP, lipid analysis of plasma revealed a significant decrease in omega-6/omega-3 ratio, correlated with a significant reduction in left ventricular mass index in SHR. The NHE1 activity was significantly higher in SHR compared with W. While in W the NHE1 activity was similar in both groups, a significant decrease in NHE1 activity was detected in SHRs supplemented with ω3 FAs, reaching values comparable with W. Altogether, these findings revealed that diet supplementation with ω3 FAs since early age prevents the development of cardiac hypertrophy in SHR, perhaps by decreasing NHE1 activity, without altering hemodynamic overload. •The early and long-term administration of omega-3 fatty acids in SHR:•Does not modify the SBP.•Prevents the development of cardiac hypertrophy.•Avoids NHE1 hyperactivation characteristic of hypertrophied myocardium.•Decreases omega- 6/omega- 3 ratio in plasma.